Compare Repligen Corporation Common Stock (RGEN) vs Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) (SMFG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) trades at $24.63 (market cap $158.90B). The key difference: Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) is far larger — about 14.3× Repligen Corporation Common Stock's market cap, and Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) pays a 2.35% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan) for 6 Days on average.
| RGEN | SMFG | |
|---|---|---|
Market Cap | $11.14B | $158.90B |
Volume | 1,259,263 | 1,175,519 |
Sector | Health | Financials |
52-Week High | $194.57 | $27.56 |
52-Week Low | $102.87 | $15.69 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.02B | $12.70T |
Dividend Yield | — | 2.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
SMFG trades at $25.21, up 0.72% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beating expectations with $0.50 EPS versus $0.44 expected, while Q4 2025 missed estimates. Revenue grew from $5.07T in 2025 to $6.14T in 2026 with net income margin improving to 27.8%. Analyst consensus shows 75% hold rating with institutional positions shifting recently.
SMFG presents a value opportunity with attractive valuation ratios (P/E 14.9, EV/EBITDA 5.16) and improving profitability, though technical weakness and mixed analyst sentiment suggest near-term caution. The stock faces risks from Japanese interest rate sensitivity and competitive pressures in global banking markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan)
Sumitomo Mitsui Financial Group is a Japanese financial services company with banking, securities, leasing, and asset management businesses. It serves retail, corporate, and institutional clients.
Read more on SMFG →
